Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

2-aminoimidazoles collapse mycobacterial proton motive force and block the electron transport chain.

Jeon AB, Ackart DF, Li W, Jackson M, Melander RJ, Melander C, Abramovitch RB, Chicco AJ, Basaraba RJ, Obregón-Henao A.

Sci Rep. 2019 Feb 6;9(1):1513. doi: 10.1038/s41598-018-38064-7.

2.

2-aminoimidazoles potentiate ß-lactam antimicrobial activity against Mycobacterium tuberculosis by reducing ß-lactamase secretion and increasing cell envelope permeability.

Jeon AB, Obregón-Henao A, Ackart DF, Podell BK, Belardinelli JM, Jackson M, Nguyen TV, Blackledge MS, Melander RJ, Melander C, Johnson BK, Abramovitch RB, Basaraba RJ.

PLoS One. 2017 Jul 27;12(7):e0180925. doi: 10.1371/journal.pone.0180925. eCollection 2017.

3.

The Discovery of 2-Aminobenzimidazoles That Sensitize Mycobacterium smegmatis and M. tuberculosis to β-Lactam Antibiotics in a Pattern Distinct from β-Lactamase Inhibitors.

Nguyen TV, Blackledge MS, Lindsey EA, Minrovic BM, Ackart DF, Jeon AB, Obregón-Henao A, Melander RJ, Basaraba RJ, Melander C.

Angew Chem Int Ed Engl. 2017 Mar 27;56(14):3940-3944. doi: 10.1002/anie.201612006. Epub 2017 Mar 1.

4.

A model of type 2 diabetes in the guinea pig using sequential diet-induced glucose intolerance and streptozotocin treatment.

Podell BK, Ackart DF, Richardson MA, DiLisio JE, Pulford B, Basaraba RJ.

Dis Model Mech. 2017 Feb 1;10(2):151-162. doi: 10.1242/dmm.025593. Epub 2017 Jan 12.

5.

Second generation 2-aminoimidazole based advanced glycation end product inhibitors and breakers.

Furlani RE, Richardson MA, Podell BK, Ackart DF, Haugen JD, Melander RJ, Basaraba RJ, Melander C.

Bioorg Med Chem Lett. 2015 Nov 1;25(21):4820-4823. doi: 10.1016/j.bmcl.2015.06.080. Epub 2015 Jun 29.

6.

Inhibition and breaking of advanced glycation end-products (AGEs) with bis-2-aminoimidazole derivatives.

Richardson MA, Furlani RE, Podell BK, Ackart DF, Haugen JD, Melander RJ, Melander C, Basaraba RJ.

Tetrahedron Lett. 2015;56(23):3406-3409.

7.

Increased severity of tuberculosis in Guinea pigs with type 2 diabetes: a model of diabetes-tuberculosis comorbidity.

Podell BK, Ackart DF, Obregon-Henao A, Eck SP, Henao-Tamayo M, Richardson M, Orme IM, Ordway DJ, Basaraba RJ.

Am J Pathol. 2014 Apr;184(4):1104-1118. doi: 10.1016/j.ajpath.2013.12.015. Epub 2014 Jan 31.

8.

Expression of antimicrobial drug tolerance by attached communities of Mycobacterium tuberculosis.

Ackart DF, Hascall-Dove L, Caceres SM, Kirk NM, Podell BK, Melander C, Orme IM, Leid JG, Nick JA, Basaraba RJ.

Pathog Dis. 2014 Apr;70(3):359-69. doi: 10.1111/2049-632X.12144. Epub 2014 Feb 24.

9.

Reversal of Mycobacterium tuberculosis phenotypic drug resistance by 2-aminoimidazole-based small molecules.

Ackart DF, Lindsey EA, Podell BK, Melander RJ, Basaraba RJ, Melander C.

Pathog Dis. 2014 Apr;70(3):370-8. doi: 10.1111/2049-632X.12143. Epub 2014 Feb 24.

10.

Non-diabetic hyperglycemia exacerbates disease severity in Mycobacterium tuberculosis infected guinea pigs.

Podell BK, Ackart DF, Kirk NM, Eck SP, Bell C, Basaraba RJ.

PLoS One. 2012;7(10):e46824. doi: 10.1371/journal.pone.0046824. Epub 2012 Oct 4.

11.

Uptake and accumulation of oxidized low-density lipoprotein during Mycobacterium tuberculosis infection in guinea pigs.

Palanisamy GS, Kirk NM, Ackart DF, Obregón-Henao A, Shanley CA, Orme IM, Basaraba RJ.

PLoS One. 2012;7(3):e34148. doi: 10.1371/journal.pone.0034148. Epub 2012 Mar 30.

12.

Evidence for oxidative stress and defective antioxidant response in guinea pigs with tuberculosis.

Palanisamy GS, Kirk NM, Ackart DF, Shanley CA, Orme IM, Basaraba RJ.

PLoS One. 2011;6(10):e26254. doi: 10.1371/journal.pone.0026254. Epub 2011 Oct 18.

Supplemental Content

Loading ...
Support Center